Tempus has added a novel MRD assay, xM, to its testing solutions.Â
FDA approved Keytruda (pembrolizumab) with chemoradiotherapy for patients with FIGO 2014 stage 3-4A cervical cancer.
The United States Patent and Trademark Office, or USPTO issued U.S. Patent No. US 11,873,348 covering ATOR-4066, a Neo-X-Prime next generation bispecific antibody targeting CD40 and CEACAM5, in the treatment of cancer.
Caris Life Sciences and Flatiron Health have partnered to create a multimodal data offering to support and accelerate biopharmaceutical drug development and patient care.
Veracyte, a global cancer diagnostics company, has acquired C2i Genomics, a company combining genomics and AI to create a whole-genome cancer intelligence platform.
The Pancreatic Cancer Action Network, or PanCAN, and the Global Coalition for Adaptive Research formed a strategic alliance to further advance research efforts for pancreatic cancer.Â
The New York Proton Center and the WiTT Group Inc. formed a strategic partnership to help patients navigate the non-clinical challenges of cancer treatment.Â
FDA has approved Welireg (belzutifan) for patients with advanced renal cell carcinoma (RCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI).
FDA has approved Padcev (enfortumab vedotin-ejfv) in combination with Keytruda (pembrolizumab) for patients with locally advanced or metastatic urothelial cancer (la/mUC).Â
The European Commission has granted marketing authorization for Jemperli (dostarlimab) in combination with carboplatin-paclitaxel, for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer and who are candidates for systemic therapy.Â
